Optic neuritis occurs due to inflammation of the optic nerve, which is also termed as papillitis (when the head of the optic nerve is involved) and retrobulbar neuritis (when the posterior of the nerve is involved). The frequency of optic neuritis varies with clinical onset before 16 years of age in different regions of Russia which may fluctuates from 2 to 10% of all MS patients. Thirty-eight children i.e..80% of them had ON at least once, ten i.e..21.3% of them had twice or more times.
Treatment usually includes steroid medications such as Orason, Deltason, Prednison, Methylprednisolone or others which can speed up the persons vision recovery time. While treatment with steroids may have little effect on the end visual outcome of people with optic neuritis, people who are under medication with intravenous steroids have the risk of developing multiple sclerosis in two years when compared to people who do not receive such treatment.
The primary aim is to develop a framework for evaluating interventions in ON and in order to assess their ability to restore normal tissue, restore optimal neurological function, re-establish normal physiology. People with optic neuritis have a good recovery of their vision and may not have any long term problems with their sight.